Boehringer Ingelheim Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved once-daily Mirapex ER (pramipexole dihydrochloride) for both early and advanced Parkinson’s disease (PD).

Mirapex ER extended-release tablets have shown good results in trials for the signs and symptoms of idiopathic Parkinson’s disease (PD), which includes early and advanced PD.

Boehringer Ingelheim Pharmaceuticals executive vice president Albert Ros said that with the approval of Mirapex ER, the company is hopeful that this once-daily treatment option may help ease some of the burden and obstacles that people with advanced Parkinson’s disease face on a daily basis.

FDA approval of Mirapex ER for advanced PD patients was supported by efficacy data from one randomised, double-blind, placebo-controlled, three-parallel group clinical study.